Health & Beauty

The FINANCIAL -- NEW YORK and TOKYO, August 22, 2018 –Pfizer Inc. and Astellas Pharma Inc.  announced amendments to the protocols for two registrational Phase 3 trials, ARCHES and EMBARK, designed to evaluate the safety and efficacy of XTANDI in men with hormone-sensitive prostate cancer (HSPC). These amendments accelerate timelines for the anticipated primary completion dates of both ...

The FINANCIAL -- Boston, MA – People who gain weight after they quit smoking may face a temporary increase in the risk of developing type 2 diabetes, with the risk directly proportional to the ...

The FINANCIAL -- ViiV Healthcare announced positive headline results from its global, phase III ATLAS study of a long-acting, injectable two-drug regimen (2DR) for the treatment of ...